← Back to Search

Topoisomerase I inhibitors

Topotecan for Brain Cancer

Phase 1 & 2
Waitlist Available
Led By Jeffrey Bruce, MD
Research Sponsored by Jeffrey N. Bruce
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment, during treatment, post treatment
Awards & highlights

Study Summary

This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental delivery technique designed to maximize the amount of drug delivered to the brain tumor and minimize the side effects in other parts of the body. This study will also evaluate advanced magnetic resonance (MR) imaging techniques. The study will assess quality of life parameters throughout the follow-up period.

Eligible Conditions
  • Brain Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during treatment, post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and during treatment, post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Grade 3 Adverse Events
Time to death
Time to tumor progression/recurrence
Secondary outcome measures
Quality of life at follow-up time points

Trial Design

1Treatment groups
Experimental Treatment
Group I: TopotecanExperimental Treatment2 Interventions
Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Topotecan
FDA approved

Find a Location

Who is running the clinical trial?

Jeffrey N. BruceLead Sponsor
1 Previous Clinical Trials
5 Total Patients Enrolled
Jeffrey Bruce, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
5 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors
Jeffrey N. Bruce 2004. "Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00308165.
All > Brain Tumor
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top